VIDEO: Risk factors of mantle cell lymphoma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The factors that contribute to patients' risk can be captured by clinical characteristics, by the Mantle cell International Prognostic Index or MIPI score. This takes into account a number of factors and can include the proliferation rate or Ki-67 of the tumor cells on the biopsy of the patient. But the other factors that have really been increasingly recognized that aren't in the MIPI score are factors including presence or absence of TP53 mutation and blastoid variant. So blastoid variant is relatively rare, maybe 10% or 15% at most, of mantle cell lymphoma. It is usually associated with an aggressive clinical course and sort of treatment refractoriness to conventional chemotherapy. In addition, there's really been more and more recognition in recent years that TP53 mutations, which can be assessed from tissue biopsies or from bone marrow, really confer chemo refractoriness to traditional agents and confer a high risk disease for male cell lymphoma.